New Concentration in Regenerative and Stem Cell Technologies

Posted in Bioinformatics, Biotechnology, Biotechnology Education, Biotechnology Enterprise, Biotechnology Enterprise and Entrepreneurship, Biotechnology/MBA, Center for Biotechnology Education, Home page featured, Individualized Genomics and Health, Post Master’s Certificate in Sequence Analysis and Genomics

Regenerative and Stem Cell Technologies Concentration
Author: Ellen Poltilove

Johns Hopkins University is launching a new concentration in Regenerative and Stem Cell Technologies within the Master of Science in Biotechnology. Students will become knowledgeable about areas including regenerative medicine, cell therapy, gene therapy and tissue engineering.

The concentration will be offered through the Krieger School of Arts and Sciences Advanced Academic Programs. Most of the courses will be offered online; the lab class has an onsite component at the Montgomery County Campus wet lab.

The concentration currently is open for enrollment.

Areas such as stem cell research, tissue engineering, gene therapy and gene editing are seeing increased market demand for biotechnology professionals, said Jamie Austin, program coordinator for the concentration.

“There’s a lot of promise for some of the therapeutic capabilities,” Austin said.

The program features one brand new course: Stem Cell Culture Laboratory Methods. Students in that course, which will be offered in July, will learn about cell cultivation methods and the basics of tissue engineering.

Another critical course to the concentration is Regenerative Medicine: Bench to Bedside; it will be offered in the fall. Students will learn about biological, engineering, clinical, legal, regulatory and ethical principles and perspectives to understand regenerative medicine. Students will learn how to bring regenerative medicine products to market.

Ten courses are required to compete the Master of Science in Biotechnology with the Regenerative and Stem Cell Technologies concentration. In addition to Bench to Bedside and the laboratory class, students must take:

  • Biochemistry
  • Molecular Biology
  • Advanced Cellular Biology I
  • Advanced Cellular Biology II
  • Gene Therapy
  • Stem Cell Biology
  • Two electives

The curriculum will evolve as research and clinical development in the field advances. The concentration, Austin said, has been developed in collaboration with industry experts and scientists. Austin expects to have guest speakers from local biotechnology companies.

Applicants must have a bachelor’s degree, with a grade point average of 3.0 or higher, from an accredited college or university. Applicants are expected to have completed a minimum of two semesters of biology; two semesters of college chemistry, preferably with a lab component; and two semesters of organic chemistry, preferable with a lab component.

Students with non-technical backgrounds will be considered on a case-by-case basis.

Possible careers for graduates include patent attorneys, entrepreneurs, scientists, lab researchers and regulatory professionals in industry or government.

More Information >